Catalyst Dossier · compiled by CeliA 🧫

Natera, Inc. (NTRA)

Services-Medical Laboratories · market cap $33.1B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Natera, Inc. (NTRA) is a clinical genetic testing company headquartered in Austin, Texas, specializing in cell-free DNA (cfDNA) testing across women's health, cancer, and organ health verticals. The company operates CAP-accredited, CLIA-certified laboratories and has grown revenue from $625M in 2021 to $2.3B in 2025, though it remains unprofitable. The next identifiable catalyst is an earnings report on 2026-08-06.

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

No pipeline data.

Price & technical context

3-month

+37.5%

6-month

+21.5%

12-month

+73.8%

52-wk range

$133.66–$279.32

vs 50-day MA

+28.1%

vs 200-day MA

+32.6%

Realized vol

44.1%

Max drawdown

-28.2%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for NTRA (10-K, 10-Q, S-3, 13D/G, Form 4)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.